Back to News
Dec 5, 2025 8:50 AM

Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval

On Thursday, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb & Co.’s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL).

Breyanzi is administered as a one-time infusion.

Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of any CD19-directed CAR T cell therapy.

Also Read: Bristol Myers Pushes Data Readout For Key Alzheimer’s Psychosis Study After Irregularities

The ...